Cristiano Matos1,2, Gerda Weits3, Florence van Hunsel3. 1. Department of Pharmacology, Faculty of Pharmacy, University of Seville, Seville, Spain. cristiano.r.matos@gmail.com. 2. Instituto Politécnico De Coimbra, ESTESC-Coimbra Health School, Farmácia, Coimbra, Portugal. cristiano.r.matos@gmail.com. 3. Netherlands Pharmacovigilance Centre Lareb, 's-Hertogenbosch, The Netherlands.
Abstract
INTRODUCTION: Patient organizations have a privileged position to be active agents for promoting pharmacovigilance and patient engagement, encouraging direct patient reporting and improving the awareness of pharmacovigilance. AIM: The objective of this study was to understand the role of European patient organizations as stakeholders to optimize patient involvement in pharmacovigilance. METHODS: A descriptive correlational study was conducted to investigate the opinions and attitudes of patient organizations regarding general patient involvement in pharmacovigilance, and their initiatives to support drug safety through a web-based questionnaire during the months of March and April 2018. RESULTS: A total of 1898 patient organizations were invited to participate in the survey, including 89 pan-European organizations. In total, 337 questionnaires (17.76%) were collected from 31 countries, including 297 complete answers (88.31%). A large number of organizations stated that they would like to increase the awareness of patients regarding specific adverse drug reactions (ADRs) related to their medicines (43.19%, n = 130); however, 38.54% (n = 116) declared they do not have any pharmacovigilance goals. Barriers to supporting pharmacovigilance activities include low budget to promote pharmacovigilance among members (45.45%, n = 135), lack of resources to participate in pharmacovigilance activities (43.77%, n = 130), or lack of support from the National Competent Authorities (33.33%, n = 99). Organizations inform patients to report ADRs (40.40%; n = 120), information regarding new ADRs related to their medicines (40.07%; n = 119), or when a new drug is marketed (30.98%; n = 92); however, more than one-third indicated that they never had any involvement in pharmacovigilance (34.68%; n = 103). CONCLUSION: Bringing pharmacovigilance stakeholders and patient organizations together could create a more optimal reporting culture. Patient organizations appear to have an important role in encouraging patients to talk with their doctors/pharmacists about ADRs experienced, or to help him/her report the ADRs to the pharmacovigilance systems. Lack of resources, budget, and support from NCAs are seen as the main barriers to being involved in pharmacovigilance awareness.
INTRODUCTION:Patient organizations have a privileged position to be active agents for promoting pharmacovigilance and patient engagement, encouraging direct patient reporting and improving the awareness of pharmacovigilance. AIM: The objective of this study was to understand the role of European patient organizations as stakeholders to optimize patient involvement in pharmacovigilance. METHODS: A descriptive correlational study was conducted to investigate the opinions and attitudes of patient organizations regarding general patient involvement in pharmacovigilance, and their initiatives to support drug safety through a web-based questionnaire during the months of March and April 2018. RESULTS: A total of 1898 patient organizations were invited to participate in the survey, including 89 pan-European organizations. In total, 337 questionnaires (17.76%) were collected from 31 countries, including 297 complete answers (88.31%). A large number of organizations stated that they would like to increase the awareness of patients regarding specific adverse drug reactions (ADRs) related to their medicines (43.19%, n = 130); however, 38.54% (n = 116) declared they do not have any pharmacovigilance goals. Barriers to supporting pharmacovigilance activities include low budget to promote pharmacovigilance among members (45.45%, n = 135), lack of resources to participate in pharmacovigilance activities (43.77%, n = 130), or lack of support from the National Competent Authorities (33.33%, n = 99). Organizations inform patients to report ADRs (40.40%; n = 120), information regarding new ADRs related to their medicines (40.07%; n = 119), or when a new drug is marketed (30.98%; n = 92); however, more than one-third indicated that they never had any involvement in pharmacovigilance (34.68%; n = 103). CONCLUSION: Bringing pharmacovigilance stakeholders and patient organizations together could create a more optimal reporting culture. Patient organizations appear to have an important role in encouraging patients to talk with their doctors/pharmacists about ADRs experienced, or to help him/her report the ADRs to the pharmacovigilance systems. Lack of resources, budget, and support from NCAs are seen as the main barriers to being involved in pharmacovigilance awareness.
Authors: Leàn Rolfes; Florence van Hunsel; Sarah Wilkes; Kees van Grootheest; Eugène van Puijenbroek Journal: Pharmacoepidemiol Drug Saf Date: 2014-07-31 Impact factor: 2.890
Authors: Leàn Rolfes; Florence van Hunsel; Laura van der Linden; Katja Taxis; Eugène van Puijenbroek Journal: Drug Saf Date: 2017-07 Impact factor: 5.606
Authors: Luís Monteiro; Matilde Monteiro-Soares; Cristiano Matos; Inês Ribeiro-Vaz; Andreia Teixeira; Carlos Martins Journal: Int J Environ Res Public Health Date: 2022-06-04 Impact factor: 4.614
Authors: Kamila Sienkiewicz; Monika Burzyńska; Izabela Rydlewska-Liszkowska; Jacek Sienkiewicz; Ewelina Gaszyńska Journal: Int J Environ Res Public Health Date: 2021-12-31 Impact factor: 3.390
Authors: Cristiano Matos; Florence van Hunsel; Rogério Tavares Ribeiro; Dulce Nascimento do Ó; João Filipe Raposo Journal: Ther Adv Drug Saf Date: 2020-09-04
Authors: Linda Härmark; Gerda Weits; Rietje Meijer; Federica Santoro; G Niklas Norén; Florence van Hunsel Journal: Drug Saf Date: 2020-08 Impact factor: 5.606